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Originality of the work 
Despite therapeutic advances, outcomes for patients with pediatric high-grade 
glioma (HGG) remain poor. HERBY was a large, international study that investigated 
bevacizumab for treatment of paediatric patients with HGG. Unlike in adult 
glioblastoma, adding bevacizumab to radiotherapy-temozolomide did not influence 
event-free survival in paediatric newly diagnosed HGG, which is important 
information for physicians. Critically, HERBY also highlighted that information 
regarding treatment of adults with HGG cannot be directly applied to children with 
HGG and it is important that pediatric-specific studies are carried out for this disease. 
Suggested running title Bevacizumab for newly diagnosed pediatric high-grade 
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ABSTRACT 
Purpose 
Bevacizumab (BEV) is approved in over 60 countries for use in adults with recurrent 
glioblastoma. We evaluated the addition of BEV to radiotherapy-temozolomide 
(RT/TMZ) in pediatric patients with newly diagnosed high-grade glioma (HGG). 
Methods 
The HERBY trial (clinicaltrials.gov NCT01390948; randomized/parallel-
group/multicenter/open-label) enrolled patients aged ≥3 to <18 years with localized, 
centrally neuropathology-confirmed, non-brainstem HGG. Eligible patients were 
randomized to receive RT/TMZ (RT, 1.8Gy, 5 days/week; TMZ, 75mg/m2/day for 6 
weeks; 4-week treatment break; then up to 12×28-day cycles of TMZ [cycle 1: 
150mg/m2/day, days 1 to 5; cycles 2 to 12: 200mg/m2/day, days 1 to 5]) with or 
without BEV (10mg/kg every 2 weeks). Primary endpoint: event-free survival (EFS), 
assessed by a Central Radiology Review Committee (CRRC) blinded to treatment. 
We report findings of EFS 12 months after enrollment of the last patient. 
Results 
One hundred and twenty-one patients were enrolled (RT/TMZ, n=59; BEV+RT/TMZ, 
n=62). CRRC-assessed median EFS did not differ significantly between the 
treatment groups (RT/TMZ, 11.8 months; 95% confidence interval [CI], 7.9 to 16.4; 
BEV+RT/TMZ, 8.2 months; 95% CI, 7.8 to 12.7; hazard ratio [HR], 1.44; P=.13 
[stratified log-rank test]). In the overall survival analysis, addition of BEV did not 
reduce the risk of death (HR, 1.23; 95% CI, 0.72 to 2.09). More patients in the 
BEV+RT/TMZ group versus the RT/TMZ group experienced ≥1 serious adverse 
event (n=35, 58% v n=27, 48%) and more patients receiving BEV discontinued study 
treatment due to adverse events (n=13, 22% v n=3, 5%). 
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Conclusion 
Adding BEV to RT/TMZ did not improve EFS in pediatric patients with newly 
diagnosed HGG. Our findings were not comparable to those of previous adult trials, 
highlighting the importance of performing pediatric-specific studies. 
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INTRODUCTION 
High-grade gliomas (HGGs) are the most common group of pediatric malignant 
central nervous system (CNS) neoplasms with an annual incidence of 0.87 per 
100,000 children in the USA.1 Despite surgical resection followed by radiotherapy 
(RT) and concomitant adjuvant chemotherapy, the prognosis for children with HGG 
remains poor. Unlike most other cancer types, 5-year survival is lower in pediatric 
versus adult patients with HGG.1,2 
There are substantial differences between pediatric and adult HGG.3-5 
Midline tumor location is more frequent in children than in adults.6,7 While contrast 
enhancement is the hallmark of malignant gliomas in adults, not all pediatric HGGs 
exhibit contrast uptake.8,9 Platelet-derived growth factor receptor alpha amplification 
is the most common DNA copy number change in pediatric HGG, while 
epidermal growth factor receptor amplification is more commonly detected in adults.5 
O6-methylguanine-DNA methyltransferase (MGMT) promoter expression is also less 
frequent in pediatric versus adult patients with HGG.10 A key difference in pediatric 
HGGs compared with adult HGGs is the presence of unique somatic H3F3A (histone 
H3.3) driver mutations at position K27M and G34R/V of the regulatory tail11, 
suggesting that results from adult trials may not be directly transferable to pediatric 
patients with the same histologically defined disease. 
Bevacizumab (BEV) is approved in more than 60 countries worldwide for use 
in adults with recurrent glioblastoma.12,13 Clinical experience with BEV in pediatric 
patients with HGG is limited, although the addition of BEV to irinotecan in 31 children 
with recurrent malignant glioma or intrinsic brainstem glioma showed some efficacy 
and was well tolerated.14 The HERBY trial aimed to evaluate the efficacy and safety 
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of adding BEV to postoperative radiotherapy/temozolomide (RT/TMZ) in pediatric 
patients with newly diagnosed, localized HGG. 
 
METHODS 
Study Design 
HERBY (HGG Efficacy and tolerability Research of Bevacizumab in Young 
children and adolescents; BO25041; clinicaltrials.gov NCT01390948) was a phase II, 
open-label, randomized, international, comparator study of the addition of BEV to 
RT/TMZ in pediatric patients (aged ≥3 to <18 years) with newly diagnosed HGG. 
Here we present event-free survival (EFS) data at 12 months after enrollment of the 
last patient. 
HERBY was conducted as part of a pediatric investigation plan and in 
accordance with applicable country regulations, International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good 
Clinical Practice guidelines, and the Declaration of Helsinki. Written informed 
consent was obtained from the patient/parents or legally acceptable representatives 
prior to enrollment and collection of tissue (for exploratory biomarker analyses). 
Eligible patients were centrally randomized 1:1, based on a minimization 
algorithm, via an interactive voice response system to receive BEV+RT/TMZ or 
RT/TMZ with the following stratification factors: age (≥3 to <6 years, ≥6 to <13 years, 
≥13 to <18 years), World Health Organization (WHO) grade (III v IV), and type of 
surgery (total/near-total resection v others) (Fig 1). Randomization was performed 
via minimization with biased coin assignment.15 Patients and investigators were not 
masked to treatment assignment; the Central Radiology Review Committee (CRRC) 
was masked to group allocation. 
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Study treatment started at least 28 days after cranial surgery and no later 
than 6 weeks following the last major surgery. Patients received RT (1.8 Gy/session, 
30 sessions, 5 days/week for a total of 54 Gy) and TMZ 75mg/m2/day for 6 weeks, 
followed by a minimum 4-week TMZ treatment break, then up to 12×28-day cycles of 
TMZ (cycle 1: 150mg/m2/day, days 1–5; cycles 2–12: 200mg/m2/day, days 1–5). 
Patients assigned to BEV treatment additionally received BEV 10mg/kg every 2 
weeks, which was delivered concomitantly with RT/TMZ (concurrent phase), alone 
during the TMZ treatment break, and subsequently with up to 12×28-day cycles of 
TMZ (adjuvant phase). Concomitant corticosteroid use and stable doses of 
anticoagulants were permitted. 
 
Patients 
Patients aged ≥3 to <18 years with newly diagnosed, localized, 
supratentorial or infratentorial cerebellar or peduncular, grade III/IV gliomas 
(according to WHO 2007 guidelines) were enrolled; local histological diagnosis was 
confirmed by a central reference neuropathologist before enrollment. Availability of a 
baseline magnetic resonance imaging (MRI) scan and the ability to commence trial 
treatment 4–6 weeks after surgery were also required. Key exclusion criteria were: 
metastatic HGG defined as evidence of neuro-axis dissemination by MRI or positive 
cerebrospinal fluid cytology; gliomatosis cerebri (extensive glioma, ie, involving at 
least three cerebral lobes according to WHO 2007 guidelines), multifocal glioma, 
diffuse intrinsic pontine glioma (DIPG), or intramedullary HGG; pleomorphic 
xanthoastrocytoma or anaplastic ganglioglioma; prior diagnosis of a malignancy 
(including low-grade glioma), and not disease free for 5 years; prior systemic 
anticancer therapy; previous cranial irradiation; any significant cardiovascular 
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disease or unresolved infection; or chronic daily treatment with aspirin (>325mg/day) 
or clopidogrel (>75mg/day). 
 
Study Assessments 
Patients were followed for a minimum of 1 year after randomization. Tumor 
progression/recurrence and BEV response were determined using Response 
Assessment in Neuro-Oncology (RANO) criteria in HGG.16 Tumor evaluations were 
performed at baseline, at the end of the TMZ break, every 3 months during the 
adjuvant phase and the first 3 years post-randomization, and every 6 months 
thereafter, until progression/recurrence.17 
Health-related quality of life was assessed in patients aged ≥5 years using 
the Health Utility Index (HUI) questionnaire,18 which was completed at screening, at 
cycle 6 of the adjuvant phase, at the end of treatment, yearly during the follow-up 
period, at the time of progression, and at the end-of-study visit. Neuropsychological 
assessment using the Wechsler scale adapted for age was measured at the end of 
treatment, every 2 years during the follow-up period, and at the end-of-study visit. 
 
Study Endpoints 
The pre-specified primary endpoint was EFS, defined as the earliest 
occurrence of any of the following: tumor progression and tumor recurrence (CRRC-
assessed); second primary non-HGG malignancy; or death attributable to any cause. 
Pre-specified secondary endpoints included overall survival (OS) and 1-year 
OS rate; 6-month and 1-year EFS rates (CRRC-assessed); objective response rate 
(ORR; CRRC-assessed using RANO criteria); investigator-assessed EFS; health 
status as measured by the HUI (patients aged ≥5 years); neuropsychological 
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function as measured by the Wechsler scale adapted for age; and safety. Post-hoc 
exploratory analyses of EFS (CRRC-assessed) and OS by histone mutation status 
and tumor location were performed. 
 
Safety 
Adverse events (AEs) and serious AEs (SAEs) were reported from study 
treatment initiation to 28 days following the last dose of study treatment. AEs of 
special interest (AESIs), regardless of relationship to study treatment, were reported 
up to 6 months following the last dose of study treatment. After 6 months, only study 
treatment-related SAEs were reported. 
 
Statistical Analysis 
Analysis populations included the intent-to-treat population (all randomized 
patients regardless of whether they received study treatment); the efficacy-evaluable 
population (all randomized patients with at least one post-randomization assessment 
from the local investigator); and the safety-evaluable population (all randomized 
patients who received at least one dose of study treatment). Baseline characteristics 
were compared between treatment groups using χ2, Mann-Whitney-Wilcoxon, or 
Kruskal-Wallis tests as appropriate. 
The primary endpoint of CRRC-assessed EFS was estimated using Kaplan-
Meier methodology and compared between treatment groups using a stratified log-
rank test (two-sided) at the 5% level of significance; stratification factors were age, 
HGG WHO grade, and extent of surgery. Estimates of treatment effect 
(BEV+RT/TMZ v RT/TMZ) stratified for covariates were expressed as hazard ratios 
(HRs) with 95% confidence intervals (CIs) estimated in a Cox model. Investigator-
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assessed EFS and OS were analyzed using a two-sided log-rank test. Safety data 
are described according to the maximum grade of intensity reported per preferred 
term, per patient. 
See the Appendix (online only) for further details on the study assessments, 
AESI definitions, and statistical analyses performed, including sample size 
calculations, interim futility analysis, and pre-specified sensitivity analyses. 
 
RESULTS 
Patients 
Between October 2011 and February 2015, 174 patients were screened (53 
patients failed screening), and 121 were randomized to receive treatment (RT/TMZ, 
n=59; BEV+RT/TMZ, n=62) (Fig 2). Overall, 116 patients (RT/TMZ, n=56; 
BEV+RT/TMZ, n=60) received study treatment at 51 sites in 14 countries.  
Baseline characteristics were balanced, with no significant differences 
between treatment groups for any of the variables listed in Table 1. MGMT promotor 
status was assessed in 42 patients, of whom 37 had an unmethylated tumor 
(RT/TMZ, n=18; BEV+RT/TMZ, n=19) (Table 1). H3F3A mutation status was 
assessed in 85 patients, of whom 31 showed evidence of a mutation (RT/TMZ, n=15; 
BEV+RT/TMZ, n=16) (Table 1). Mutations were observed at position K27M in 24 
patients (RT/TMZ, n=10; BEV+RT/TMZ, n=14) and at position G34R/V in seven 
patients (RT/TMZ, n=5; BEV+RT/TMZ, n=2) (Table 1). Additional MGMT promotor 
and histone mutation status findings from subsequent analyses using non-pre-
specified tests are reported in a separate paper (Mackay A, et al. [In submission]). 
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The median duration of survival follow-up was similar between treatment 
groups (RT/TMZ, 15.2 months [range, 0.1–46.8 months]; BEV+RT/TMZ, 16.2 
months [range, 0–45.7 months]). 
 
Interim Analysis 
The study was considered futile following the pre-specified interim analysis 
(performed after the first 60 randomized patients were followed for 1 year). However, 
since patient recruitment had been completed and there were no safety concerns by 
the time the interim analysis was performed, the Independent Data Monitoring 
Committee recommended continuing treatment of ongoing patients as per the 
protocol. 
 
Primary Efficacy Endpoint 
Median CRRC-assessed EFS for RT/TMZ and BEV+RT/TMZ was 11.8 
months (95% CI, 7.9–16.4) and 8.2 months (95% CI, 7.8–12.7), respectively 
(stratified HR, 1.44; 95% CI, 0.90–2.30; P=.13) (Fig 3). The earliest contributing 
event was tumor progression (RT/TMZ, n=35; BEV+RT/TMZ, n=38), death (n=3 
each group), tumor recurrence (RT/TMZ, n=1; BEV+RT/TMZ, n=4), and second 
primary non-HGG malignancy (n=1 each group; osteosarcoma [RT/TMZ] and B cell 
acute lymphocytic leukemia [BEV+RT/TMZ]). Results were generally consistent 
across the different subgroups (Fig 4), although females receiving RT/TMZ showed a 
better outcome than those receiving BEV+RT/TMZ (HR, 2.10; 95% CI, 1.04–4.21). 
 
Secondary Efficacy Endpoints 
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The 1-year CRRC-assessed EFS rates were 48% (95% CI, 35–61) and 38% 
(95% CI, 26–51) for RT/TMZ and BEV+RT/TMZ, respectively; the 1-year OS rates 
were 68% (95% CI, 54–78) and 75% (95% CI, 61–84), respectively. Due to the 
absence of measurable lesions at baseline, only 27 patients were eligible for CRRC-
assessed ORR analysis. Among these patients, the ORR was 40% (6/15 patients) 
and 42% (5/12 patients) in the RT/TMZ and BEV+RT/TMZ groups, respectively. 
Results for investigator-assessed EFS (HR, 1.49; 95% CI, 0.92–2.40) were similar to 
those for CRRC-assessed EFS. The addition of BEV did not reduce the risk of death 
OS (HR, 1.23; 95% CI, 0.72–2.09) (Fig 5).OS data are immature; a final OS analysis 
will be performed at the study . The most common pattern of progression in both 
groups was local recurrence (RT/TMZ, n=25; BEV+RT/TMZ, n=23); more patients in 
the BEV+RT/TMZ group (n=15) than in the RT/TMZ group (n=8) showed both local 
and distant recurrence. 
 
Treatment Received 
During the concurrent phase, 95% and 98% of patients treated with RT/TMZ 
and BEV+RT/TMZ, respectively, completed ≥90% of planned RT doses, and 86% 
and 88% of patients completed ≥90% of planned TMZ doses. Correspondingly, 
during the adjuvant phase, 45% and 33% of patients completed 12 TMZ cycles. The 
total and per cycle TMZ dose received was comparable between groups for the 
concurrent and adjuvant phases. Patients in the BEV+RT/TMZ group received a 
median of 5.0 and 18.5 BEV administrations during the concurrent and adjuvant 
phases, respectively. 
 
Safety 
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The median duration of safety follow-up was 11.7 months and 11.6 months 
in the RT/TMZ and BEV+RT/TMZ groups, respectively. No new safety signals were 
identified for BEV. All patients, except one in the BEV+RT/TMZ group, experienced 
at least one AE. The incidence of grade 3 to 5 AEs was similar across the groups 
(RT/TMZ, n=38 [68%] v BEV+RT/TMZ, n=42 [70%]) but more patients experienced a 
grade 3 to 5 AESI in the BEV+RT/TMZ group (n=13, 22%) than in the RT/TMZ group 
(n=3, 5%). The most common AESIs were proteinuria (RT/TMZ, n=0 [0%] v 
BEV+RT/TMZ, n=8 [13%]) and arterial thromboembolic events (RT/TMZ, n=2 [4%] v 
BEV+RT/TMZ, n=5 [8%]). More patients experienced at least one SAE in the 
BEV+RT/TMZ group (n=35, 58%) than in the RT/TMZ group (n=27, 48%) and a 
higher proportion of patients discontinued any component of study treatment due to 
AEs in the BEV+RT/TMZ group (n=13, 22%) than in the RT/TMZ group (n=3, 5%). 
More patients in the BEV+RT/TMZ group (n=43, 72%) experienced AEs leading to 
dose modifications of any component of study treatment than in the RT/TMZ group 
(n=34, 61%). 
In the BEV+RT/TMZ group, BEV and TMZ were discontinued due to AEs in 
20% and 5% of patients, respectively. Among patients who discontinued BEV due to 
an AE, the most common reason was proteinuria (n=6, 10%). At the clinical cut-off 
date, four of the proteinuria events had resolved following BEV discontinuation, and 
two were ongoing. 
Deaths occurred in 28 patients (50%) in the RT/TMZ group and 33 patients 
(55%) in the BEV+RT/TMZ group; the cause of death in all but one patient was 
disease progression. One treatment-related grade 4 AE of atypical teratoid/rhabdoid 
tumor of the CNS occurred in the BEV+RT/TMZ group 2 years after the end of study 
treatment and resulted in death. 
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See the Appendix (online only) for further details on patient disposition and 
protocol deviations in this study and results of the interim futility analysis, sensitivity 
analyses, health-related quality of life and neuropsychological function assessments, 
and exploratory analyses of potential prognostic factors. 
 
DISCUSSION 
The HERBY study evaluated the efficacy and safety of BEV/RT/TMZ versus RT/TMZ 
alone in pediatric patients with newly diagnosed non-brainstem HGG. Based on a 
pre-specified interim analysis of the first 60 randomized patients who were followed 
for 1 year, the study was considered futile. However, since patient recruitment had 
been completed and there were no safety concerns, the Independent Data 
Monitoring Committee recommended the continued treatment of patients as per the 
protocol. This publication presents the updated analysis of the enrolled 121 patients 
in the main protocol who were followed for at least 1 year after randomization, unless 
patient withdrawal or death occurred. 
There was no significant difference in CRRC-assessed EFS (primary 
endpoint) between treatment groups, and the results of the secondary endpoints, 
including investigator-assessed EFS, ORR, and OS, showed no improvement with 
the addition of BEV. No new safety signals were identified for BEV. However, a 
higher proportion of patients in the BEV+RT/TMZ group than in the RT/TMZ group 
discontinued study treatment due to toxicity. Patients in the RT/TMZ group had a 
higher-than-expected 1-year EFS rate of 48% (95% CI, 35–61), which is comparable 
with previously reported 1-year EFS rate of 38% with RT/TMZ,2 and  49% with TMZ 
plus lomustine.19 
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The absence of an EFS benefit with BEV in our study is not consistent with 
adult trials in which BEV has been shown to delay radiological progression (although 
neither adult study showed an OS benefit).20,21 Biological differences between 
pediatric and adult HGGs may partly explain why children respond differently to 
treatments.3,4 Most patients in our study had non-contrast-enhancing lesions at 
baseline (79%), while adult HGGs are typically contrast-enhancing.8 Also, the 
proportion of patients in our study with MGMT unmethylated tumors was lower than 
reported in adult patients with HGG,10 suggesting a phenotypic difference. This 
highlights the importance of conducting pediatric-specific HGG trials to assess the 
benefit of potential treatments. 
Between-group differences in tumor location may also have contributed to 
the lower-than-anticipated efficacy seen with BEV, 39% of patients in the 
BEV+RT/TMZ group had midline tumors versus 31% in the RT/TMZ group. Indeed, a 
previous study has shown poorer outcomes in patients with midline tumors versus 
other locations (although the study did not describe how midline was defined).22 In 
the current study, midline location was associated with poorer EFS than tumors in 
other locations (Appendix Results, online only). Additionally, the impact of some 
biologic prognostic factors that were not anticipated at the time of the study design 
may have affected survival. Histone mutations at K27M, which are observed in 
midline tumors, have been associated with a poor prognosis, while mutations at 
G34R/V (observed in hemispheric tumors) may be associated with slightly longer 
OS.23 In our study, H3F3A driver mutations at position K27M and G34M were 
associated with lower survival (Appendix Results, online only). Some differences in 
the proportion of patients with these mutations were evident between groups; 
however, this finding should be interpreted with caution as multiple statistical tests 
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were performed in a relatively small number of samples. MGMT methylation status 
has also been shown to influence response to TMZ.24 However, MGMT methylation 
was relatively balanced between groups for the relatively small number of patients 
assessed for MGMT methylation status in this study. 
The most common pattern of progressive disease in both groups was local 
recurrence, although a greater proportion of patients receiving BEV showed both 
local and distant progression. Previous research has suggested that BEV may lead 
to a higher incidence of distant and diffuse disease in pediatric patients with HGG or 
DIPG,25 and adult studies have noted a greater proportion of distant lesions in 
patients receiving BEV,26 although other studies reported no change in the 
radiographic pattern of patients’ tumors between baseline and the time of disease 
progression in patients receiving BEV.27 
Limitations of this study include the heterogeneity of enrolled patients, the 
relatively short follow-up duration, and the low completion rate of the HUI 
questionnaire at follow-up. The statistical power of the study was limited by the 
relatively small number of enrolled patients; however, increasing the study sample 
size would be unlikely to change the point estimate for survival, but may reduce the 
associated CI. Despite this, HERBY is one of the largest prospective, randomized 
pediatric HGG trials to date, including a molecular evaluation of tumor 
characteristics, and providing a global picture of treatment efficacy. We have 
demonstrated the feasibility of real-time, central histopathologic review before study 
entry, with no delay in treatment initiation. Only 5% of patients were excluded for 
having non-eligible low-grade glioma, compared with up to 30% in a trial that used 
post-hoc central review.27 The availability of results within 4 years of the adult trial 
demonstrates successful pharma-academic cooperation. 
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CONCLUSION 
Adding BEV to RT/TMZ did not improve EFS in pediatric patients with newly 
diagnosed HGG. These results are not fully consistent with adult studies and 
highlight the biological differences between adult and childhood HGG, and the 
importance of performing pediatric-specific studies. 
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FIGURE LEGENDS 
Fig 1. Study design. BEV, bevacizumab; HGG, high-grade glioma; RT, radiotherapy; 
TMZ, temozolomide. 
Fig 2. CONSORT flow diagram. Note: survival follow-up was an unlimited follow-up 
that continued to capture patient survival after regular follow-up had been completed. 
Five randomized patients did not receive treatment (RT/TMZ: withdrew consent, n=3; 
BEV+RT/TMZ: failed to meet eligibility criteria, n=1; withdrew consent, n=1). BEV, 
bevacizumab; FU, follow-up; RT, radiotherapy; TMZ, temozolomide. 
Fig 3. CRRC-assessed event-free survival with RT/TMZ and BEV + RT/TMZ 
(primary efficacy endpoint). BEV, bevacizumab; CI, confidence interval; CRRC, 
Central Radiology Review Committee; HR, hazard ratio; RT, radiotherapy; TMZ, 
temozolomide. 
Fig 4. Forest plot of CRRC-assessed event-free survival for the overall cohort and 
subgroups. BEV, bevacizumab; CI, confidence interval; CRRC, Central Radiology 
Review Committee; HGG, high-grade glioma; MGMT, O6-methyguanine-DNA 
methyltransferase; NE, not evaluable; RT, radiotherapy; TMZ, temozolomide; WHO, 
World Health Organization. 
Fig 5. Overall survival with RT/TMZ and BEV + RT/TMZ (interim assessment). BEV, 
bevacizumab; CI, confidence interval, HR, hazard ratio; RT, radiotherapy; TMZ, 
temozolomide. 
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Table 1. Patient Baseline Characteristics of the ITT Population (All Randomized Patients 
Regardless of Whether They Received Study Treatment) 
Characteristic 
RT/TMZ 
(n=59) 
BEV+RT/TMZ 
(n=62) 
Total 
(n=121) 
Median age, years (range) 11.0 (3 to 17) 10.0 (3 to 17) 11.0 (3 to 17) 
Age group, n (%)* 
3 to < 6 years 
6 to < 13 years 
13 to < 18 years 
 
6 (10) 
30 (51) 
23 (39) 
 
10 (16) 
35 (57) 
17 (27) 
 
16 (13) 
65 (54) 
40 (33) 
Male, n (%) 36 (61) 34 (55) 70 (58) 
WHO grade HGG, n (%)* 
III 
IV 
 
17 (29) 
42 (71) 
 
20 (32) 
42 (68) 
 
37 (31) 
84 (69) 
Surgery, n (%)* 
Total/near-total resection 
Other resection 
Biopsy 
 
29 (49) 
20 (34) 
10 (17) 
 
31 (50) 
19 (31) 
12 (19) 
 
60 (50) 
39 (32) 
22 (18) 
MGMT gene promotor status, n (%) 
Methylated 
Unmethylated with ratio < 0.6 
Missing 
 
2 (3) 
18 (31) 
39 (66) 
 
3 (5) 
19 (31) 
40 (65) 
 
5 (4) 
37 (31) 
79 (65) 
Histone mutation status, n (%) 
No mutation 
Mutation at position G34 
Mutation at position K27 
Missing 
 
29 (49) 
5 (9) 
10 (17) 
15 (25) 
 
25 (40) 
2 (3) 
14 (23) 
21 (34) 
 
54 (45) 
7 (6) 
24 (20) 
36 (30) 
Location of HGG, n (%)    
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Midline 
Other 
18 (31) 
41 (69) 
24 (39) 
38 (61) 
42 (35) 
79 (65) 
Residual tumor at baseline, n (%)† 
Contrast-enhancing lesions 
Non-contrast-enhancing lesions 
 
15 (25) 
47 (80) 
 
12 (19) 
49 (79) 
 
27 (22) 
96 (79) 
Abbreviations: BEV, bevacizumab; HGG, high-grade glioma; ITT, intent-to-treat; MGMT, 
O6-methyguanine-DNA methyltransferase; RT, radiotherapy; TMZ, temozolomide; WHO, 
World Health Organization. 
*Stratification factors for randomization.  
†Patients could have both enhancing and non-enhancing lesions. 
 
 
 
 





